138 results about "Hypolipidemic Agents" patented technology

The invention relates to a statins antilipemic drugs furazan nitroxides derivates and a preparation method thereof, and solves the problems of nonlipid-lowering and low activity in statins antilipemic drugs and adverse effect. The invention is shown as formula (1).

Compounds are provided which have the structure wherein Q is C or N; R2a, R2b, R2c, X1 to X7, R1, R2, R3, R3a, R4, A, Y, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents. The present invention further provides a method for treating obesity and dyslipidemia in mammals including humans through simultaneous inhibition of peroxisome proliferator activated receptor-γ (PPARγ) and stimulation of peroxisome proliferator activated receptor-α (PPARα).

The invention relates to the technical field of medicines, and provides application of metrn1 protein in preparation of a lipid-lowering drug or a health-care food. An in vivo experiment shows that the blood lipid level of metrn1 fat cell specificity overexpression mice is obviously lower than that of normal mice when the normal mice and the metrn1 fat cell specificity overexpression mice are supplied with triglyceride lavage; the result shows that the metrn1 protein has an effect of reducing blood lipid. The metrn1 protein is intrinsic protein of a human body. Therefore, the safety of the metrn1 protein as a potential drug is high.

The invention provides a nigre resource obtained by the alkali refining of rice bran crude oil. The preparation technology comprises the following steps of: by taking diethyl ether as an extract solvent, washing nigre by diethyl ether of which the weight is 3-10 times as heavy as the weight of the nigre, separating fatty acid from phytosterol-containing rice bran oil, freezing the rice bran oil, crystallizing, separating out phytosterol crude product and rice bran oil, dissolving the phytosterol curde product by 94%-97% of ethanol, and decoloring by adding activated carbon to obtain phytosterol finished product finally. The phytosterol extracted from the rice bran crude oil is all natural, free from toxicity and side effects, less in damage to phytosterol products, good in beta-sitosterol retaining property, high in content which can be more than 40%, low in solvent loss, higher in yield, better in safety, and is more suitable for the addition agent and the like for pharmacy (antilipemic agent), food and cosmetics.

The present invention relates to a combination, such as a combined preparation or pharmaceutical composition comprising: (a) compound of formula (I), and / or (II) or a pharmaceutically acceptable salt thereof; (b) at least one therapeutic agent selected from the group consisting of: an antihypertensive agent; an antidiabetics agent; a hypolipidemic agent; an antiplatelet agent; an antiobesity agent; an antithrombotic agent; an agent for diabetic vascular complications; and an agent for treatment of heart failure; or a pharmaceutically acceptable salts thereof, optionally in presence of a pharmaceutically acceptable carrier for separate, simultaneous or sequential use. The present invention also relates to a use of such combination for the treatment of mammal including human being. R1, R2, R3, R1, R2, R3, R4, R5, X, Y, A and B and m are as defined in the specification.

The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar1” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH2)p′(CH2)pB(CH2)q′(CH2)rB(CH2)pD(CH2)p′ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R4 represents hydrogen, alkyl, alkenyl, —S(O)2—R8 or —C(O)R8 where R8 is alkyl, alkoxy; R5 and R6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R5 and R6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.

Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.

The invention discloses new dihydrogen homoisoflavonoid, and a preparation method and application thereof. The new dihydrogen homoisoflavonoid is separated to extract polygonatum sibiricum. Experiments prove that the dihydrogen homoisoflavonoid can remarkably inhibit lipid accumulation in Hep-G2 cells, also can remarkably reduce the triglyceride (TG) content and the total cholesterol (TC) content of the cells, is more excellent that a positive control medicine simvastatin in the aspect of reducing the TG, and has excellent blood fat-reducing activity. The discovery of the new dihydrogen homoisoflavonoid provides a new lead compound for developing a new blood fat-reducing medicine, and good development and application prospect is achieved. The preparation process is simple, stable and reliable, the purity of the compound is high (above 98 percent), industrialized popularization is facilitated, a new approach is opened up for research and development of the blood fat reducing medicines, and good social and economic benefits are achieved.

The present invention relates to the stable pharmaceutical composition of a suitable hypolipidemic agent. Preferably, the present invention discloses novel formulations of the compound of formula (I), or pharmaceutically acceptable salts of compounds of formula (I). More particularly the present invention relates to the stable pharmaceutical composition of compounds of formula (I) comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7.

The invention belongs to the field of biological medicine, and specifically relates to an application of a lignan compound in the preparation of drugs for reducing blood fat. The disclosed triterpene lignan compound is (-)-syringaresinol-4-O-glucoside, and the structural formula of the lignan compound is represented by the formula (I). The provided compound can prominently inhibit lipid accumulation in-vitro, is capable of obviously reducing the cholesterol and triglyceride in the animal blood of a hyperglycemia model, and has a prominent effect on reducing blood fat. The lignan compound can be used as a novel drug for reducing blood fat, and can be used to treat hyperglycemia, and the drug is user-friendly.

The invention belongs to the technical field of medicine and specifically provides methylpyrazine derivative biological arginine hydrate, a preparation method thereof and application thereof in preparing blood fat reducing medicine. The prepared methylpyrazine derivative biological arginine hydrate disclosed by the invention is radiated by Cu-K alpha, and an X ray diffraction spectrogram represented by 2 theta has the characteristic peaks at the 5.7+ / -0.2 degree, 9.1+ / -0.2 degree, 16.2+ / -0.2 degree, 24.5+ / -0.2 degree, 24.8+ / -0.2 degree and 27.8+ / -0.2 degree positions. The prepared methylpyrazine derivative biological arginine hydrate disclosed by the invention has high stability; the purity basically cannot change when the methylpyrazine derivative biological arginine hydrate is placed ina dissolved state and a solid state; the solubility of the methylpyrazine derivative biological arginine hydrate in different media is 2.5 times of an existing crystal form; furthermore, the methylpyrazine derivative biological arginine hydrate has the advantages of higher bioavailability and better industrial application prospect.

A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient.Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and / or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and / or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.